US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

C.R. Bard

331.24

0.0000

Volume:- -

Turnover:- -

Market Cap:24.07B

PE:47.05

High:331.24

Open:331.24

Low:331.24

Close:331.24

52wk High:337.73

52wk Low:223.02

Shares:72.67M

Float Shares:71.68M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):7.04

ROE:--

ROA:--

PB:12.98

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288

First Patient Dosed in Pivotal Phase 3 Study of TLX591-Px (Illuccix®) for Prostate Cancer Imaging in Japanese Patients

Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288

Precision Medicine Portfolio Update: Illuccix China Phase 3 Study, TLX101-CDx and TLX250-CDx FDA Resubmissions

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BCR"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BCR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCR\",,,,,undefined,":{"symbol":"BCR","market":"US","secType":"STK","nameCN":"C.R. Bard","latestPrice":331.24,"timestamp":1575666000000,"preClose":331.24,"halted":4,"volume":0,"delay":0,"changeRate":0,"floatShares":71675642,"shares":72671504,"eps":7.04,"marketStatus":"Delisted","change":0,"latestTime":"12-06 16:00:00 EST","open":331.24,"high":331.24,"low":331.24,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":7.04,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":165556800000,"exchange":"NYSE","adjPreClose":331.24,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCR\",,,,,undefined,":{"symbol":"BCR","floatShares":71675642,"roa":"--","roe":"--","lyrEps":0,"shares":72671504,"dividePrice":0,"high":331.24,"amplitude":0,"preClose":331.24,"low":331.24,"week52Low":223.02,"pbRate":"12.98","week52High":337.73,"institutionHeld":0.806,"latestPrice":331.24,"eps":7.04,"divideRate":0,"volume":0,"delay":0,"ttmEps":7.04,"open":331.24},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BCR\",params:#limit:5,,,undefined,":[{"market":"US","date":"2017-12-07","symbol":"BCR","amount":0.26,"name":"巴德","currency":"USD","type":"dividend","dateTimestamp":1512622800000},{"market":"US","date":"2017-10-25","symbol":"BCR","fiscalQuarterEnding":"2017/09","expectedEps":2.96,"name":null,"time":"","type":"earning","dateTimestamp":1508904000000,"reportTimeType":"","actualEps":3.02},{"market":"US","date":"2017-07-27","symbol":"BCR","fiscalQuarterEnding":"2017/06","expectedEps":2.84,"name":null,"time":"","type":"earning","dateTimestamp":1501128000000,"reportTimeType":"","actualEps":2.92},{"market":"US","date":"2017-07-20","symbol":"BCR","amount":0.26,"name":"巴德","currency":"USD","type":"dividend","dateTimestamp":1500523200000},{"market":"US","date":"2017-04-27","symbol":"BCR","amount":0.26,"name":"巴德","currency":"USD","type":"dividend","dateTimestamp":1493265600000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BCR\",market:\"US\",,,undefined,":[{"executeDate":"2017-01-19","recordDate":null,"paymentDate":null,"value":0.26,"currency":"USD"},{"executeDate":"2017-04-27","recordDate":null,"paymentDate":null,"value":0.26,"currency":"USD"},{"executeDate":"2017-07-20","recordDate":null,"paymentDate":null,"value":0.26,"currency":"USD"},{"executeDate":"2017-12-07","recordDate":null,"paymentDate":null,"value":0.26,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BCR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BCR\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2609533068","title":"Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288","url":"https://stock-news.laohu8.com/highlight/detail?id=2609533068","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609533068?lang=en_us&edition=fundamental","pubTime":"2026-02-06 07:30","pubTimestamp":1770334200,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, Feb.  05, 2026  (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/05/3233530/0/en/Ascentage-Pharma-Announces-IND-Clearance-by-the-China-CDE-for-BTK-Degrader-APG-3288.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2240825500.USD","LU1223082196.USD","LU2089283258.USD","LU1923622291.USD","LU2023251221.USD","LU0124676726.USD","IND","LU1712237335.SGD","BK4588","LU1223083913.SGD","LU2041044095.USD","LU2271345857.HKD","PK","LU1939255532.USD","LU1892829315.USD","LU2463526074.USD","LU2238339852.HKD","LU1430594728.SGD","LU0511384066.AUD","BK4585","LU2125909916.SGD","LU2413666426.HKD","WM","LU1917777945.USD","LU1923621640.USD","BCR","LU2125909759.SGD","AAPG","LU0347712357.USD","BK4181","LU0289960550.SGD","LU2106854487.HKD","LU2298064838.USD","LU2111349929.HKD","LU2362540622.SGD","LU2362541513.USD","CDE","LU2308191902.HKD","APG","LU1989772840.SGD","LU2089284900.SGD","LU2413666699.HKD","LU0289739343.SGD","LU1989772923.USD","LU0158827948.USD","BK4139","BK4533","LU0057025933.USD","LU0472753341.HKD","LU2023250504.SGD"],"gpt_icon":0},{"id":"2607722363","title":"First Patient Dosed in Pivotal Phase 3 Study of TLX591-Px (Illuccix®) for Prostate Cancer Imaging in Japanese Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2607722363","media":"prnewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607722363?lang=en_us&edition=fundamental","pubTime":"2026-01-29 07:43","pubTimestamp":1769643780,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia, Jan. 29, 2026 /PRNewswire/ --Telix Pharmaceuticals Limited  today announces that the first patient has been dosed in the Phase 3 registration study of TLX591-Px  for prostate cancer imaging in Japanese patients. The patient was dosed at Shonan Kamakura General Hospital  in Kamakura, Japan.Illuccix Japan[1] is a Phase 3 prospective, open-label, multicenter study designed to evaluate the detection efficacy and safety profile of 68Ga-PSMA-11 PET/CT[2] in Japanese patients with biochemically recurrent  prostate cancer following prior radical prostatectomy. The study will enroll up to 105 Japanese men at 11 sites and data are intended to support a future marketing authorization application for TLX591-Px in Japan.The primary objective of the study is to compare the sensitivity of 68Ga-PSMA-11 PET/CT to conventional imaging  for the detection of metastatic lesions. Secondary objectives include evaluating diagnostic performance for local and distant lesions, safety and to","market":"nz","thumbnail":"https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/first-patient-dosed-in-pivotal-phase-3-study-of-tlx591-px-illuccix-for-prostate-cancer-imaging-in-japanese-patients-302673282.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4543","TLX","BK4141","BK7039","ASX.AU","BK7067","BCR","TLX.AU","ASX","BK4526","SEC.AU"],"gpt_icon":0},{"id":"2601479768","title":"Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288","url":"https://stock-news.laohu8.com/highlight/detail?id=2601479768","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601479768?lang=en_us&edition=fundamental","pubTime":"2026-01-07 09:00","pubTimestamp":1767747600,"startTime":"0","endTime":"0","summary":"Novel next-generation Bruton tyrosine kinase (BTK)-targeted protein degrader APG-3288 has receivedinvestigational new drug (IND) clearancefrom the U.S. FDA, marking another major expansion to the comp","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/07/3214213/0/en/Ascentage-Pharma-Announces-IND-Clearance-by-the-U-S-Food-and-Drug-Administration-for-BTK-Degrader-APG-3288.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","LU0124676726.USD","WM","LU2125909916.SGD","LU2362541513.USD","BK4129","BK4585","LU1623119135.USD","BCR","LU0057025933.USD","LU2125910179.SGD","LU0069063385.USD","LU1430594728.SGD","LU2041044095.USD","LU2211814178.USD","LU2355687059.USD","LU1917777945.USD","LU1923622291.USD","LU1923621640.USD","BK4181","LU1892829315.USD","LU0289739343.SGD","BK4534","LU2125910336.SGD","LU2308191902.HKD","LU2362540622.SGD","LU1939255532.USD","LU0511384066.AUD","AAPG","BK4120","PK","APG","IND","LU2089279066.USD","LU0689626769.HKD","LU2238339852.HKD","BK4588","LU2240825500.USD","LU0347712357.USD","LU0472753341.HKD","LU1712237335.SGD","LU2229751404.USD","LU0289961442.SGD","LU1585245621.USD","LU1989772840.SGD","LU2023250504.SGD","LU2125909759.SGD","LU2413666699.HKD","LU1974910355.USD","BK4139"],"gpt_icon":0},{"id":"2593175686","title":"Precision Medicine Portfolio Update: Illuccix China Phase 3 Study, TLX101-CDx and TLX250-CDx FDA Resubmissions","url":"https://stock-news.laohu8.com/highlight/detail?id=2593175686","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593175686?lang=en_us&edition=fundamental","pubTime":"2025-12-22 05:38","pubTimestamp":1766353080,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and INDIANAPOLIS, Dec.  22, 2025  (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today provides a precision medicine portfolio update in relati","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/21/3208918/0/en/Precision-Medicine-Portfolio-Update-Illuccix-China-Phase-3-Study-TLX101-CDx-and-TLX250-CDx-FDA-Resubmissions.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0390134368.USD","LU2237443895.HKD","BK4217","IE00BHPRN162.USD","CMC","BK4530","LU2237443465.HKD","IE00B1BXHZ80.USD","LU2746668974.SGD","LU2746668461.USD","BK4585","IE00BKVL7J92.USD","LU0029874061.USD","LU0128526141.USD","LU2237443382.USD","BK4588","BK4006","LU0971096721.USD","LU2237443622.USD","TLX","PSA","BK4121","LU0170899867.USD","BK4141","BK4543","IE00BFXG1179.USD","LU1815336091.USD","BCR","CRL","LU2237443549.SGD","LU0149725797.USD","BK4139","IE00BFMHRM44.USD","ASX","LU1363072403.SGD","LU0757428866.USD","LU2237443978.SGD","BK4084","IE00BZ1G4Q59.USD","LU0267386448.USD","BK4526","LU0882574139.USD","BK4533"],"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":7,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/BCR\",params:#limit:6,delay:false,,,undefined,":[]}}